Advantest: the chip tester too expensive for its own good

2026-07-07 · By Lubin Danilo, founder of Lubin Investment

6857.T: see the full analysis on Lubin Investment

Advantest makes the machines that test semiconductors before they reach the market, a niche business where it shares a near-monopoly with a single global rival. It passes all 10 criteria in my screener, but trades at roughly 74 times its free cash flow, one of the most extreme valuations I track.

Key takeaways

• Advantest passes all 10 criteria in my screener, a rare result I only see in a handful of companies.
• The stock trades at roughly 74 times its free cash flow, one of the most extreme valuations in my entire tracked universe.
• Free cash flow per share grows 38.7% a year on average over five years, driven by AI-related chip demand.
• A deliberate contrast with KLA Corporation, covered the same day: same sector, same AI wave, opposite valuation.

What Advantest does

Advantest makes the testing equipment that verifies an electronic chip works correctly before it leaves the factory, an essential step in the semiconductor production chain. The global chip testing market is dominated by a very small number of players, with Advantest and Teradyne as the main global suppliers, a market structure close to a duopoly.

A perfect score, driven by the AI wave

Advantest passes all ten of my financial criteria: 20.7% net margin, 44.4% cash return on invested capital, negative net debt, and above all free cash flow per share up 38.7% a year on average over five years. This acceleration is directly tied to explosive demand for AI chips, which require more complex and therefore more expensive testing than generic chips.

A price at the opposite end from KLA Corporation

I analyzed KLA Corporation the same day, another semiconductor equipment maker that passes 9 of the 10 criteria in my screener but trades at only 7.7 times its free cash flow. Advantest, with a perfect score and faster growth, nonetheless trades at nearly ten times that multiple, at 74 times its free cash flow. That's an interesting teaching contrast: within the same sector riding the same technology wave, two companies of comparable or higher quality can trade at radically different multiples, depending on how directly the market associates them with the artificial intelligence narrative.

The moat: a global duopoly

Advantest's moat comes from the extremely high technological barrier to designing testing equipment capable of keeping pace with the miniaturization of the most advanced chips. With Teradyne as its only comparably sized global rival, this market functions almost like a duopoly, durably protecting the positions and margins of both established players.

The real risk: the price, not the company

At this valuation level, the main risk isn't the company's quality but the price paid to own it. A P/FCF of 74 assumes current AI-driven growth persists for many years. A simple slowdown in the historically cyclical semiconductor cycle, or a temporary pause in AI chip manufacturing capacity investment, could sharply compress this multiple, even without any deterioration in the company's underlying quality.

What to keep in mind

Advantest illustrates a case where fundamental quality is beyond doubt, but where the price demands very strong conviction about the durability of the current AI demand cycle. That's not a reason to automatically rule it out, but a reason to never confuse 'excellent company' with 'good investment at any price.'

What I take away from this

Advantest and KLA Corporation, analyzed the same day in the same sector, perfectly illustrate why I always judge quality and price separately. Advantest's quality is beyond doubt; it's the price that raises a real question, one the dominant AI narrative tends to make people forget.

FAQ

What does Advantest do?

It makes the testing equipment that verifies an electronic chip works correctly before it leaves the factory, a niche business dominated by a very small number of global players.

Why is Advantest so expensive when KLA Corporation isn't?

The market associates Advantest more directly with the artificial intelligence narrative, inflating its valuation despite a quality score only slightly higher than KLA's.

Does Advantest have a real competitor?

Teradyne is its only comparably sized global rival, a market structure close to a duopoly.

What is the main risk with Advantest?

The price paid, not the company's quality: a P/FCF of 74 assumes durable AI-driven growth for many years, and a slowdown in the semiconductor cycle could sharply compress this multiple.

Is Advantest in debt?

No, its net debt is negative: it holds more cash than total debt.

6857.T: see the full analysis on Lubin Investment

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I find fundamental analysis fascinating, and it has delivered excellent results. For three years now, my performance has beaten the S&P 500. But analyzing every stock took too much time: sites with incomplete data, calculation methods and criteria never aligned with mine. And spotting the best stocks was just as time-consuming, even with my own well-defined checklist. So I put my software development background to work to build this software, base my investment strategy on its results, and share it with people who share the same passion as me. It judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).